Clifton Barry Photo.jpg

Dr. Clifton E. Barry III received his Ph.D. in organic and bio-organic chemistry in 1989 from Cornell University, studying the biosynthesis of complex natural products. Following postdoctoral research in the chemistry department at Johns Hopkins University (1989 to 1992), Dr. Barry joined the Intramural Research Program of the National Institute of Allergy and Infectious Diseases’ (NIAID’s) Rocky Mountain Laboratories in Hamilton, Montana. In 1998, he was tenured as chief of the Tuberculosis Research Section (TRS) in the Laboratory of Clinical Infectious Diseases of NIAID.

The TRS is a multidisciplinary group of research scientists comprised of biologists, chemists and clinicians who share a common focus on TB. TRS projects focus on understanding the scientific issues that facilitate the development of drugs that will make a genuine difference in the outcome for TB patients globally. TRS scientists are highly interactive worldwide in this endeavor and as a result of our outstanding collaborations TRS is the most highly cited TB research group in the world according to Thomson Reuters. Dr Barry has authored over 300 publications in the scientific literature. Working with scientists at PathoGenesis in Seattle, TRS played a key role in the preclinical development program that led to PA-824 (Pretomanid, recently approved for treating drug resistant TB). TRS scientists conceived and conducted the Phase 2 clinical trial showing the utility of using linezolid for the treatment of patients suffering from extensively drug-resistant tuberculosis now recommended by WHO.
In addition to TRS laboratories in Bethesda TRS works closely with Chinese colleagues at the Henan Provincial Chest Hospital in Zhengzhou, China; and with colleagues at Stellenbosch University (SUN) and the University of Cape Town (UCT) in South Africa. Dr. Barry holds honorary appointments at both UCT and SUN and has a growing laboratory in the Institute for Infectious Disease and Molecular Medicine.